|
1
|
Fernández Y, Cueva J, Palomo AG, Ramos M,
de Juan A, Calvo L, García-Mata J, García-Teijido P, Peláez I and
García-Estévez L: Novel therapeutic approaches to the treatment of
metastatic breast cancer. Cancer Treat Rev. 36:33–42. 2010.
View Article : Google Scholar
|
|
2
|
Beaumont T and Leadbeater M: Treatment and
care of patients with metastatic breast cancer. Nurs Stand.
25:49–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Watanabe T: Treatment of metastatic breast
cancer patients: What is the standard care of the patients? Jpn J
Clin Oncol. 28:355–356. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schneider BP, Winer EP, Foulkes WD, Garber
J, Perou CM, Richardson A, Sledge GW and Carey LA: Triple-negative
breast cancer: Risk factors to potential targets. Clin Cancer Res.
14:8010–8018. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Laurentiis M, Cianniello D, Caputo R,
Stanzione B, Arpino G, Cinieri S, Lorusso V and De Placido S:
Treatment of triple negative breast cancer (TNBC): Current options
and future perspectives. Cancer Treat Rev. 36(Suppl 3): S80–S86.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chacón RD and Costanzo MV: Triple-negative
breast cancer. Breast Cancer Res. 12(Suppl 2): S32010. View Article : Google Scholar :
|
|
8
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anders CK and Carey LA: Biology,
metastatic patterns, and treatment of patients with triple-negative
breast cancer. Clin Breast Cancer. 9(Suppl 2): S73–S81. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hudis CA and Gianni L: Triple-negative
breast cancer: An unmet medical need. Oncologist. 16(Suppl 1):
1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Drummond DC, Noble CO, Kirpotin DB, Guo Z,
Scott GK and Benz CC: Clinical development of histone deacetylase
inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol.
45:495–528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu T, Kuljaca S, Tee A and Marshall GM:
Histone deacetylase inhibitors: Multifunctional anticancer agents.
Cancer Treat Rev. 32:157–165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kikuchi H, Barman HK, Nakayama M, Takami Y
and Nakayama T: Participation of histones, histone modifying
enzymes and histone chaperones in vertebrate cell functions.
Subcell Biochem. 40:225–243. 2006.
|
|
14
|
Konstantinopoulos PA, Karamouzis MV and
Papavassiliou AG: Focus on acetylation: The role of histone
deacetylase inhibitors in cancer therapy and beyond. Expert Opin
Investig Drugs. 16:569–571. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Johnstone RW: Histone-deacetylase
inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug
Discov. 1:287–299. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vigushin DM and Coombes RC: Histone
deacetylase inhibitors in cancer treatment. Anticancer Drugs.
13:1–13. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Richon VM and O'Brien JP: Histone
deacetylase inhibitors: A new class of potential therapeutic agents
for cancer treatment. Clin Cancer Res. 8:662–664. 2002.PubMed/NCBI
|
|
18
|
Lin HY and Chen CS, Lin SP, Weng JR and
Chen CS: Targeting histone deacetylase in cancer therapy. Med Res
Rev. 26:397–413. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim HJ and Bae SC: Histone deacetylase
inhibitors: Molecular mechanisms of action and clinical trials as
anticancer drugs. Am J Transl Res. 3:166–179. 2011.PubMed/NCBI
|
|
20
|
Xu WS, Parmigiani RB and Marks PA: Histone
deacetylase inhibitors: Molecular mechanisms of action. Oncogene.
26:5541–5552. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang C, Fu M, Angeletti RH, Siconolfi-Baez
L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S,
Hopp T, et al: Direct acetylation of the estrogen receptor alpha
hinge region by p300 regulates transactivation and hormone
sensitivity. J Biol Chem. 276:18375–18383. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gaughan L, Logan IR, Cook S, Neal DE and
Robson CN: Tip60 and histone deacetylase 1 regulate androgen
receptor activity through changes to the acetylation status of the
receptor. J Biol Chem. 277:25904–25913. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bouchalova K, Cizkova M, Cwiertka K,
Trojanec R and Hajduch M: Triple negative breast cancer - current
status and prospective targeted treatment based on Her1 (EGFR),
TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky
Olomouc Czech Repub. 153:13–17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rao R, Balusu R, Fiskus W, Mudunuru U,
Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja P,
et al: Combination of pan-histone deacetylase inhibitor and
autophagy inhibitor exerts superior efficacy against
triple-negative human breast cancer cells. Mol Cancer Ther.
11:973–983. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang S, Huang J, Lyu H, Lee CK, Tan J,
Wang J and Liu B: Functional cooperation of miR-125a, miR-125b, and
miR-205 in entinostat-induced downregulation of erbB2/erbB3 and
apoptosis in breast cancer cells. Cell Death Dis. 4:e5562013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Clin Chem. 55:623–631. 2009.
View Article : Google Scholar
|
|
28
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar :
|
|
30
|
Scott GK, Mattie MD, Berger CE, Benz SC
and Benz CC: Rapid alteration of microRNA levels by histone
deacetylase inhibition. Cancer Res. 66:1277–1281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vogel C and Marcotte EM: Insights into the
regulation of protein abundance from proteomic and transcriptomic
analyses. Nat Rev Genet. 13:227–232. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maier T, Güell M and Serrano L:
Correlation of mRNA and protein in complex biological samples. FEBS
Lett. 583:3966–3973. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mestdagh P, Boström AK, Impens F, Fredlund
E, Van Peer G, De Antonellis P, von Stedingk K, Ghesquière B,
Schulte S, Dews M, et al: The miR-17-92 microRNA cluster regulates
multiple components of the TGF-β pathway in neuroblastoma. Mol
Cell. 40:762–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu S, Huang S, Ding J, Zhao Y, Liang L,
Liu T, Zhan R and He X: Multiple microRNAs modulate p21Cip1/Waf1
expression by directly targeting its 3′ untranslated region.
Oncogene. 29:2302–2308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moasser MM: The oncogene Her2: Its
signaling and transforming functions and its role in human cancer
pathogenesis. Oncogene. 26:6469–6487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schoeberl B, Faber AC, Li D, Liang MC,
Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, et al: An
ErbB3 antibody, MM-121, is active in cancers with ligand-dependent
activation. Cancer Res. 70:2485–2494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schoeberl B, Pace EA, Fitzgerald JB, Harms
BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, et al:
Therapeutically targeting ErbB3: A key node in ligand-induced
activation of the ErbB receptor-PI3K axis. Sci Signal. 2:ra312009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aurisicchio L, Marra E, Roscilli G,
Mancini R and Ciliberto G: The promise of anti-ErbB3 monoclonals as
new cancer therapeutics. Oncotarget. 3:744–758. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Holbro T, Beerli RR, Maurer F, Koziczak M,
Barbas CF III and Hynes NE: The ErbB2/ErbB3 heterodimer functions
as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor
cell proliferation. Proc Natl Acad Sci USA. 100:8933–8938. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee-Hoeflich ST, Crocker L, Yao E, Pham T,
Munroe X, Hoeflich KP, Sliwkowski MX and Stern HM: A central role
for Her3 in Her2-amplified breast cancer: Implications for targeted
therapy. Cancer Res. 68:5878–5887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu B, Ordonez-Ercan D, Fan Z, Edgerton
SM, Yang X and Thor AD: Downregulation of erbB3 abrogates
erbB2-mediated tamoxifen resistance in breast cancer cells. Int J
Cancer. 120:1874–1882. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang S, Huang X, Lee CK and Liu B:
Elevated expression of erbB3 confers paclitaxel resistance in
erbB2-overexpressing breast cancer cells via upregulation of
Survivin. Oncogene. 29:4225–4236. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chuang JC and Jones PA: Epigenetics and
microRNAs. Pediatr Res. 61:24R–29R. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Veeck J and Esteller M: Breast cancer
epigenetics: From DNA methylation to microRNAs. J Mammary Gland
Biol Neoplasia. 1:5–17. 2010. View Article : Google Scholar
|
|
45
|
Su X, Qian C, Zhang Q, Hou J, Gu Y, Han Y,
Chen Y, Jiang M and Cao X: miNomes of haematopoietic stem cells and
dendritic cells identify miR-30b as a regulator of Notch1. Nat
Commun. 4:29032013. View Article : Google Scholar
|
|
46
|
Drogaris P, Villeneuve V, Pomiès C, Lee
EH, Bourdeau V, Bonneil E, Ferbeyre G, Verreault A and Thibault P:
Histone deacetylase inhibitors globally enhance h3/h4 tail
acetylation without affecting h3 lysine 56 acetylation. Sci Rep.
2:2202012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huang X, Gao L, Wang S, Lee CK, Ordentlich
P and Liu B: HDAC inhibitor SNDX-275 induces apoptosis in
erbB2-overexpressing breast cancer cells via down-regulation of
erbB3 expression. Cancer Res. 69:8403–8411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou Q, Agoston AT, Atadja P, Nelson WG
and Davidson NE: Inhibition of histone deacetylases promotes
ubiquitin-dependent proteasomal degradation of DNA
methyltransferase 1 in human breast cancer cells. Mol Cancer Res.
6:873–883. 2008. View Article : Google Scholar : PubMed/NCBI
|
